John A Copland Iii (John A Copland)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Radical Prostatectomy

Top Venues

Molecular cancer therapeutics

bioRxiv : the preprint server for biology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics 23 (6) (2024)
Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics 23 (6) (2024)
Jason Shirian, Alexandra Hockla, Justyna Joanna Gleba, Mathew A Coban, Naama Rotenberg, Laura M Strik, Aylin A Demirer, Matt L Pawlush, John A Copland Iii, Evette S Radisky, Julia M Shifman
Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension. bioRxiv : the preprint server for biology (2024)
Jason Shirian, Alexandra Hockla, Justyna Joanna Gleba, Mathew A Coban, Naama Rotenberg, Laura M Strik, Aylin A Demirer, Matt L Pawlush, John A Copland Iii, Evette S Radisky, Julia M Shifman
Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension. bioRxiv : the preprint server for biology (2024)
Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer. Molecular cancer therapeutics (2024)
Vilma Dembitz, Hannah Lawson, Richard Burt, Sirisha Natani, Céline Philippe, Sophie C James, Samantha Atkinson, Jozef Durko, Lydia M Wang, Joana Campos, Aoife M S Magee, Keith Woodley, Michael James Austin, Ana Rio-Machin, Pedro Casado, Findlay Bewicke-Copley, Giovanny Rodriguez Blanco, Diego Pereira-Martins, Lieve Oudejans, Emeline Boet, Alex von Kriegsheim, Juerg Schwaller, Andrew J Finch, Bela Patel, Jean-Emmanuel Sarry, Jerome Tamburini, Jan Jacob Schuringa, Lori Hazlehurst, John A Copland Iii, Mariia Yuneva, Barrie Peck, Pedro Rodriguez Cutillas, Jude Fitzgibbon, Kevin Rouault-Pierre, Kamil R Kranc, Paolo Gallipoli
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation. Leukemia (2024)
Jing Deng, Aneel Paulus, Douglas D Fang, Alak Manna, Guangfeng Wang, Hengbang Wang, Saijie Zhu, Jianyong Chen, Ping Min, Yan Yin, Navnita Dutta, Nabanita Halder, Gina Ciccio, John A Copland Iii, James L Miller, Bing Han, Longchuan Bai, Liu Liu, Mi Wang, Donna McEachern, Sally Przybranowski, Chao-Yie Yang, Jeanne A Stuckey, De-Pei Wu, Caixia Li, Jeremy Adam Ryan, Anthony G Letai, Sikandar Ailawadhi, Dajun Yang, Shaomeng Wang, Asher A Chanan-Khan, Yifan Zhai
Lisaftoclax (APG-2575) is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)